Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
A phase 1/2 trial of Ramucirumab and Sacituzumab tirumotecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) is a phase 1/2 interventional study registered as NCT06445972 by Merck Sharp & Dohme LLC, with 210 participants planned, started 2024-08-07 and due to reach its primary completion in 2028-05-09. Interventions recorded: Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan, Rescue Medications and HER3-DXd.
Similar pages
not linked directly; found by shared links- TrialA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
- TrialSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Shares Sacituzumab tirumotecan, Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
- TrialA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
- TrialSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares Daiichi Sankyo, Merck & Co. (MSD), Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD) and the tag pipeline.
- TrialA Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Shares Sacituzumab tirumotecan, Daiichi Sankyo, Merck & Co. (MSD) and the tag pipeline.